All In Biotech

Drug Trial Radar · NCT05266456

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years

Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 835 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

835

Actual

Start

Feb 22, 2022

Primary completion

Jan 10, 2023

Study completion Jan 10, 2023

Sponsor

Lead sponsor
Vaxcyte, Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.

Conditions

  • Pneumococcal Vaccines

Interventions

  • 24 valent pneumococcal conjugate vaccineBiological

    0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

  • 20 valent pneumococcal conjugate vaccineBiological

    0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age GroupTime frame: 7 days after vaccination
  2. Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age GroupTime frame: 7 days after vaccination
  3. Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age GroupTime frame: 1 month after vaccination
  4. Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI)Time frame: 6 months after vaccination

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel RCA

    Hollywood, Florida

  • Precision Clinical Research

    Sunrise, Florida

  • Meridian Clinical Research

    Savannah, Georgia

  • Velocity Clinical Research

    Valparaiso, Indiana

  • Johnson County Clin-Trials

    Lenexa, Kansas

  • Benchmark Research

    Metairie, Louisiana

  • Alliance for Multispecialty Research

    Kansas City, Missouri

  • Rochester Clinical Research

    Rochester, New York

  • Acellacare of Wilmington

    Wilmington, North Carolina

  • Velocity Clinical Research

    Warwick, Rhode Island

  • Coastal Carolina Research

    North Charleston, South Carolina

  • Benchmark Research

    San Angelo, Texas

  • JBR Clinical Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.